Lung Therapeutics

6 articles about Lung Therapeutics

• Lung Therapeutics Receives SBIR Award for Kidney Fibrosis Research; Principal Investigator BreAnne Mackenzie Will Speak at 4th Annual IPF Summit 2020/Digital

  8/21/2020

  Lung Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for orphan, pulmonary indications, has been awarded a Small Business Innovation Research Grant of $300,228 from the National Institutes of Health to study potential therapies that target fibrotic processes in the kidneys.

• 

  Lung Therapeutics to Advance Clinical Assets Following $36 Million Infusion of Cash

  6/5/2019

  The funding will be used to advance clinical development of its lead asset, a treatment for loculated pleural effusions, which is a serious complication of pneumonia.

• Lung Therapeutics, Inc. Raises $36 Million in Series C Financing to Advance Clinical Pipeline

  6/4/2019

  Proceeds to fund completion of Phase II Clinical Trial for drug candidate LTI-01 in Loculated Pleural Effusions and Phase I Clinical Trial for Idiopathic Pulmonary Fibrosis (IPF) candidate LTI-03

• Lung Therapeutics, Inc. Announces New Chief Financial Officer and Board Member

  2/4/2019

  Lung Therapeutics, Inc. announced the hiring of Charles T. Garner as Chief Financial Officer and the appointment of R.A. Session, II, to the company’s Board of Directors.

• Lung Therapeutics Raises $14.3 Million Series B Financing To Treat Unmet Needs In Lung Disease And Fibrosis

  6/6/2017

• Lung Therapeutics Doses First Patient In Phase I Clinical Trial Of LTI-01 In Australia And New Zealand

  3/14/2017